Biovitrum Ab

Pharmacophotonics, Inc.

Pharmacia & Upjohn Ab

Astrazeneca Ab

Pharmacia Ab

Cytiva Bioprocess R&d Ab

Proximagen Limited

Biovitrum Ab (publ)

Erik Ringberg

Björn M Nilsson

Ulf J Bremberg

Wei Berts

James S Strickland

Anthony De Belder

Katarina Beierlein

Benjamin Pelcman

Rolf A Johansson

Jan Tejbrant

Martin Haraldsson

Markus Thor

Birger Sjoberg

Jonas Nilsson

Mattias Jönsson

Bengt L Lindqvist

Rune Ringom

Peter Brandt

Kristin Hammer

Eva ANGkerblom

Birgitta Weinz

Gary Johansson

Magnus Munck Af Rosenschöld

Robert Rönn

Bj&ouml;rn M Nilsson

Antonios Nikitidis

Grigorios Nikitidis

Petra Johannesson

Anders Hagvall

Rikard Emond

Christian Tyrchan

Jonas Gustafsson

Johan Angbrant

Linn Carlsson

David Jansson

Peter Nilsson

Wesley Ralph Schaal

Birger Sjöberg

Mattias J&ouml;nsson

Ian Vagberg

Björn Nilsson

Berts Wei

Susanna Lindberg

Sofia Henriksson

Carl Jonas Lindh

Hanna Birgitta Ellinor Andersson

Bengt Lindqvist

The invention discloses method for manufacturing agar or agarose beads, comprising the steps of: a) providing a water phase comprising an aqueous solution of agar or agarose at a temperature of 40-100° C.: b) providing an oil phase comprising a water-immiscible solvent and an emulsifier at a temperature of 40-100° C.; c) emulsifying the water phase in the oil phase to form a water-in-oil emulsion: d) cooling the water-in-oil emulsion to a temperature below a gelation temperature of the agar or agarose to form a dispersion of solidified agar or agarose beads: and e) recovering agar or agarose beads from dispersion, wherein the emulsifier comprises a phosphate ester of an alkoxylated fatty alcohol.

Method of manufacturing agar or agarose beads

The present invention relates generally to novel rhodamine dyes which upon conjugation with another molecule form single isomeric conjugation products. These novel rhodamine dyes contain only one single functional group on the rhodomine molecule for conjugation so that their conjugation products are single isomeric conjugation products.

Rhodamine dyes and conjugates

There is provided compounds of formula I, wherein E, E, E, E, L, Y, Y, Y, Rand z have meanings provided in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene Csynthase is desired and/or required, and particularly in the treatment of respiratory diseases and inflammation.

Compounds and uses

The present invention relates to compounds of the formula (I) wherein A, X and Rto Rare as described herein; to pharmaceutical compositions comprising the said compounds; to processes for their preparation; and to the use of the compounds as medicaments against 5-HTreceptor-related disorders.

[object Object]

The present invention relates to novel compounds of formula (I): 

4-substituted indole and indoline compounds

The invention relates to compounds of the general formula (I): wherein The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).

Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

Compounds of the general formula (I):  Further included are pharmaceutical compositions comprising the compounds, processes for their preparation, as well as the use of the compounds for the preparation of a medicament which particularly acts on the central nervous system, particularly for use as anti-obesity agents.

Compounds and their use

The invention relates to compounds of the general Formula (I):  The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of Formula (I).

Compounds, their use and preparation

The invention relates to compounds of the general formula (I):wherein The compounds may be prepared by per se conventional methods and can be used for treating a human or animal subject suffering from a serotonin-related disorder, such as eating disorders, especially obesity, memory disorders, schizophrenia, mood disorders, anxiety disorders, pain, sexual dysfunctions, and urinary disorders. The invention also relates to such use as well as to pharmaceutical compositions comprising a compound of formula (I).

Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases

The invention relates to novel compounds of Formula (I) wherein R,, R,, R,, R,, R,, R,, R,and Ar are as defined in claim,their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The compounds have anticholinergic activity, and the invention also relates to the compounds of Formula (I), the use of the compounds of Formula (I) for preparing anticholinergic drugs, the use of the compounds of Formula (I) for treating urinary tract incontinence, and methods for preparing the compounds of Formula (I).

Therapeutically active diarylpropylamines; their pharmaceutically acceptable salts; a method for their preparation and method for their use

Growing community of inventors

Uppsala, Sweden

Erik Ringberg